Original Article

You have full text access to this OnlineOpen article

Pretransplantation [18-F]fluorodeoxyglucose positron emission tomography scan predicts outcome in patients with recurrent Hodgkin lymphoma or aggressive non-Hodgkin lymphoma undergoing reduced-intensity conditioning followed by allogeneic stem cell transplantation

  1. Anna Dodero MD1,†,*,
  2. Roberto Crocchiolo MD2,
  3. Francesca Patriarca MD3,
  4. Rosalba Miceli MD4,
  5. Luca Castagna MD5,
  6. Fabio Ciceri MD2,
  7. Stefania Bramanti MD5,
  8. Niccolo Frungillo MD1,
  9. Raffaella Milani MD1,
  10. Flavio Crippa MD6,
  11. Federico Fallanca MD7,
  12. Emanuela Englaro MD8,
  13. Paolo Corradini MD1,9

Article first published online: 21 JUL 2010

DOI: 10.1002/cncr.25357

Issue

Cancer

Cancer

Volume 116, Issue 21, pages 5001–5011, 1 November 2010

Additional Information

How to Cite

Dodero, A., Crocchiolo, R., Patriarca, F., Miceli, R., Castagna, L., Ciceri, F., Bramanti, S., Frungillo, N., Milani, R., Crippa, F., Fallanca, F., Englaro, E. and Corradini, P. (2010), Pretransplantation [18-F]fluorodeoxyglucose positron emission tomography scan predicts outcome in patients with recurrent Hodgkin lymphoma or aggressive non-Hodgkin lymphoma undergoing reduced-intensity conditioning followed by allogeneic stem cell transplantation. Cancer, 116: 5001–5011. doi: 10.1002/cncr.25357

Author Information

  1. 1

    Division of Hematology and Bone Marrow Transplantation, Scientific Institute for Hospitalization and Treatment, Istituto Nazionale dei Tumori, Milan, Italy

  2. 2

    Scientific Institute-San Raffaele Hospital, Milan, Italy

  3. 3

    Department of Hematology, University of Udine, Udine, Italy

  4. 4

    Medical Statistics Department, Scientific Institute for Hospitalization and Treatment, Istituto Nazionale dei Tumori, Milan, Italy

  5. 5

    Department of Hematology, Humanitas Clinical Institute, Rozzano, Italy

  6. 6

    Department of Nuclear Medicine, Scientific Institute for Hospitalization and Treatment, Istituto Nazionale dei Tumori, Milan, Italy

  7. 7

    Department of Nuclear Medicine, Scientific Institute-San Raffaele Hospital, Milan, Italy

  8. 8

    Department of Nuclear Medicine, University of Udine, Udine, Italy

  9. 9

    Department of Hematology, University of Milan, Milan, Italy

  1. †

    Fax: (011) 39 0223902092

*Division of Hematology and Bone Marrow Transplantation, Scientific Institute for Hospitalization and Treatment, Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy

  1. †

    Fax: (011) 39 0223902092

Publication History

  1. Issue published online: 21 JUL 2010
  2. Article first published online: 21 JUL 2010
  3. Manuscript Accepted: 25 FEB 2010
  4. Manuscript Revised: 22 FEB 2010
  5. Manuscript Received: 2 AUG 2009

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (316K)

Keywords:

  • positron emission tomography;
  • allogeneic transplantation;
  • Hodgkin lymphoma;
  • aggressive non-Hodgkin lymphoma

Abstract

BACKGROUND:

The use of positron emission tomography (PET) scanning in Hodgkin lymphoma (HL) and aggressive non-Hodgkin lymphoma (HG-NHL) has recognized prognostic value in patients who are receiving chemotherapy or undergoing autologous stem cell transplantation (SCT). In contrast, the role of PET before reduced-intensity conditioning (RIC) and followed by allogeneic SCT has not been investigated to date.

METHODS:

PET was used to assess 80 patients who had chemosensitive disease (34 patients with HG-NHL and 46 patients with HL) before they underwent allogeneic SCT: 42 patients had negative PET studies, and 38 patients had positive PET studies. Patients underwent allograft from matched related siblings (n = 41) or alternative donors (n = 39).

RESULTS:

At the time of the last follow-up, 48 patients were alive (60%), and 32 had died. The 3-year cumulative incidence of nonrecurrence mortality and disease recurrence was 17% and 40%, respectively. The cumulative incidence of disease recurrence was significantly lower in the PET-negative patients (25% vs 56%; P = .007), but there was no significant difference between the patients with or without chronic graft-versus-host disease (P = .400). The patients who had negative PET studies before undergoing allogenic SCT also had significantly better outcomes in terms of 3-year overall survival (76% vs 33%; P = .001) and 3-year progression-free survival (73% vs 31%; P = .001). On multivariate analysis, overall survival was influenced by PET status (hazard ratio [HR], 3.35), performance status (HR, 5.15), and type of donor (HR, 6.26 for haploidentical vs sibling; HR, 1.94 for matched unrelated donor vs sibling).

CONCLUSIONS:

The current results indicated that PET scanning appears to be an accurate tool for assessing prognosis in patients who are eligible for RIC allografting. Cancer 2010. © 2010 American Cancer Society.

View Full Article (HTML) Get PDF (316K)